News

Synspira’s SNSP113 gives antibiotics more punch against the Burkholderia cepacia infections that cystic fibrosis patients experience, a study reports. The research, published in PLoS One, was titled “Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.” Lung infections caused by Burkholderia cepacia are difficult to…

A first-grader with cystic fibrosis (CF), Conor Fink, inspired a close family friend to hop on his bicycle and spend his summer pedaling from the West to East Coast — Oregon to New York — to  raise money for Claire’s Place Foundation, a nonprofit helping children and families affected by the disease.

Anthera Pharmaceuticals has received news that could help it accelerate patient enrollment in a Phase 3 clinical trial of Sollpura (liprotamase) as a treatment for a digestive disorder known as cystic fibrosis-triggered exocrine pancreatic insufficiency. The news is that a key Cystic Fibrosis Foundation committee approved the company’s trial design. The sign-off…

A Phase 3 study of Sollpura (liprotamase), a non-porcine enzyme replacement therapy aiming to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) better than existing porcine-derived therapies, is now recruiting about 150 pediatric and adult patients in the United States, Europe and Israel. Specifically, the expanded trial will evaluate the efficacy — or non-inferiority — of Sollpura compared…

A deeper understanding of how bacteria like Pseudomonas aeruginosa acts and survives in people despite antibiotic treatment was the focus of a doctoral thesis, along with a recommendation for antibiotic combinations that might work better those what’s currently in use. The thesis, “Host-pathogen interactions in Pseudomonas aeruginosa invasive and respiratory tract infection,” is by…

A computer program created by physicians in Cincinnati may help cystic fibrosis (CF) patients to keep using those at-home treatments they feel are most effective, by providing them an easy way of sharing their preferences — and a given therapy’s effectiveness — with their doctors. CF patients rely on a variety of home therapies, from…

Proteostasis Therapeutics has filed an Investigational New Drug application with the U.S. Food and Drug Administration for PTI-808 as a treatment for cystic fibrosis. PTI-808 promotes the activity of the cystic fibrosis transmembrane conductance regulator, or CFTR, the protein that is faulty in CF. Scientists call the drug a potentiator…

Cystic Fibrosis Foundation Therapeutics (CFFT) will increase funding to support Spyryx Biosciences‘ Phase 2 trial assessing SPX-101 in people with cystic fibrosis. The funding is part of an award Spyryx received in 2015 from CFFT, the Cystic Fibrosis Foundation‘s…

Children with cystic fibrosis (CF) have less sleep and more sleep interruptions than healthy children, even when the disease is well-managed and stable, an Australian study indicates. The research, “How Well Do Children with Cystic Fibrosis Sleep? An Actigraphic and Questionnaire-Based Study,” was published in The Journal of…

Forty cystic fibrosis patients or family members are winners of Vertex Pharmaceuticals‘ first All in for CF scholarships. The awards are for $5,000, making the total for the 2017-2018 academic year $200,000. Boston-based Vertex is a biotech company that develops therapies for cystic fibrosis and  other life-threatening conditions. The company…